Trial of radioactive drug for gastric and pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests a radioactive drug that targets a protein called Claudin 18.2 found on some stomach and pancreatic cancer cells. Researchers will track where the drug goes in your body and how it exits, to see if it's a safe and effective way to deliver radiation directly to tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have stomach (gastric) cancer or pancreatic cancer that has been confirmed by a biopsy
- Your cancer cells have a specific protein called Claudin 18.2 on their surface
- At least one of your tumors must have this Claudin 18.2 protein
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of PET scan (a special imaging test) that can detect a protein called claudin 18.2 in pancreatic cancer and stomach cancer. The scan may help doctors better understand your cancer and plan treatment.
This trial tests a new targeted drug (FG-M108) combined with standard chemotherapy, compared to chemotherapy alone, for people with advanced pancreatic cancer that has not been treated before. It is for those whose tumors have a specific protein (Claudin18.2) that the drug is designed to attack.
This early-stage trial tests a new drug called SNA014 for pancreatic cancer. The drug targets a specific protein marker (Claudin-18.2) on cancer cells, and researchers want to see if it's safe and effective for patients whose tumors have this marker.
This trial is testing an investigational drug called AZD5863 for people whose stomach, esophagus, or pancreatic cancer has spread and hasn't responded to at least one previous treatment. The study aims to see if targeting a protein called Claudin 18.2 on tumor cells can help shrink or slow the cancer.
This early-stage trial tests a new experimental drug called HT547 that combines radioactive tracers to help doctors see and treat certain solid tumors (breast, head and neck, pancreatic, or brain cancer). The study will check if the drug is safe, how it moves through your body, and how much radiation it gives you.
This Phase 2 study tests new combination treatments for advanced stomach or stomach-esophagus junction cancer that cannot be removed by surgery. It may help people whose tumors are positive for a marker called Claudin18.2, which the study uses to choose who can receive the treatment.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.